Scottish deep-tech company Chemify has received £22 million ($29.7 million) in grants from Scottish Enterprise and the UK Government. The funding will support a significant expansion of Chemify’s capacity to digitise molecular discovery, synthesis and scale-up through a new Chemifarm. The grant package includes £16… Read More
Chemify has unveiled its first Chemifarm—a fully automated chemistry facility regarded as the world’s most advanced laboratory for molecular design and synthesis. Situated in Glasgow’s Maryhill district, the site unites Chemify’s AI-driven molecular-design engine with industrial-scale robotic synthesis, compressing the journey from concept to compound and accelerating… Read More
Scientists have unlocked new details on important ‘receptor’ proteins – promising targets for the creation of novel drugs for metabolic conditions ranging from diabetes to obesity and inflammatory disorders. The discovery – led by the University of Glasgow, Queens University Belfast and the University of… Read More
Scientists have taken an important step toward the development of a potential new treatment for treating Shiga toxin-producing E coli (STEC), the bacteria associated with severe food poisoning. The findings – led by the University of Glasgow and published in Antimicrobials and… Read More
Earlier this year, Elaine Duncan spoke with DDW’s Diana Spencer in a Meet the Researcher interview. At the European Laboratory Research & Innovation Group (ELRIG)’s annual event, Drug Discovery 2024, she again spoke with DDW and told Megan Thomas about her journey to her current multifaceted role both at… Read More
In two separate studies, malaria researchers are exploring the potential of a long-acting injectable preventive compound and an approach from cancer treatments that could be used as a single-dose cure. Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first clinical trial for their… Read More
CV6 Therapeutics has initiated patient dosing in a Phase Ia clinical trial evaluating its investigational first-in-class, specific dUTPase inhibitor CV6-168 + infusional 5-fluorouracil (5-FU). The study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumour activity for CV6-168 in the treatment of patients with advanced… Read More
Researchers have discovered a way of using engineered brain parasites to deliver treatments for neurological conditions across the blood-brain-barrier. The study – led by the University of Glasgow in collaboration with Tel Aviv University and an international team of researchers – represents an exciting new field… Read More
A new partnership between NHS Scotland, AstraZeneca and the Universities of Dundee and Glasgow hopes to accelerate research into treating chronic kidney disease. The partners will work together on new medicines to slow the progression of chronic kidney disease, reducing the risk that patients might need… Read More
Scientists have created the first bioengineered bone marrow model which can support the type of human stem cells that are crucial for bone marrow transplants and in vitro study work. The research – published in Nature Communications and led by the University of… Read More
DDW’s Diana Spencer speaks to Elaine Duncan, a PhD student on the lifETIME (Engineered Tissues for Discovery, Industry and Medicine) CDT at the University of Glasgow. DS: Can you tell us what you do and what you’re working on at the moment? ED: I’m currently a… Read More
Recent SARS-CoV-2 variants such as BA.4 and BA.5 developed abilities missing from the first Omicron variants that allowed them to overcome humans’ innate immunity, according to research from University College London (UCL). The study examined viral evolution in eight Omicron variants to better understand how the… Read More
With leading academic institutions and significant recent investment, Glasgow is shaping up to be an important centre for drug discovery and development in the UK. DDW’s Diana Spencer explores the city’s unique ecosystem. In early December 2023, the University of Glasgow announced plans to construct a… Read More
The University of Glasgow and Kadans Science Partner, supported by Scottish Enterprise, have announced plans to construct a new Health Innovation Hub in Govan in Glasgow. It is hope that the new centre, which is due for completion in summer 2025, will set the stage for… Read More
Glox Therapeutics has raised £4.3M ($5.2M) in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The company will use the funding to establish laboratories in Oxford and Glasgow and expand its team to accelerate its bacteriocin development programme. Glox Therapeutics is developing… Read More
Scientists have discovered a new class of compound that is potentially active against trypanosome parasites that cause human African trypanosomiasis (or sleeping sickness) and Chagas disease. The findings – led by researchers at the University of Glasgow and Novartis Global Health (formerly Novartis Institutes for Tropical… Read More
